Literature DB >> 19308805

Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre.

K Y Kang1, H W Yim, I-J Kim, J U Yoon, J H Ju, H-Y Kim, S-H Park.   

Abstract

OBJECTIVE: The aim of this study was to determine whether the incidence of cancer has increased among patients with systemic sclerosis (SSc) in Korea.
METHODS: The study subjects consisted of 112 patients who had been consecutively evaluated for at least 6 months between 1990 and 2007. We retrospectively reviewed their medical records, investigated the incidence rate of cancer and compared it with that of the Korea National Cancer Centre database.
RESULTS: Nine out of 112 patients developed cancer (four males and five females). The average age at diagnosis of cancer was 56.4 years and the mean disease duration was 8.9 years. The standardized incidence ratio (SIR) for SSc patients was 4.2 [95% confidence interval (CI) 2.3-6.1], 3.7 for women (95% CI 1.2-6.2) and 6.4 for men (95% CI 1.6-11.2). Lung cancer was the most common cancer (n = 4), followed by oesophagus (n = 1), stomach (n = 1), liver (n = 1), pancreas (n = 1), and squamous cell carcinoma of unknown origin (n = 1). All patients who developed lung cancer were female and non-small cell carcinoma in origin. The SIR of lung cancer in female patients was 23.0 (95% CI 6.0-40.0). Two out of four lung cancer patients had concomitant interstitial lung disease (ILD); all were non-smokers. Treatment agents, autoantibodies, smoking, and lung involvement were not significantly different between SSc patients with or without cancer.
CONCLUSION: The SIR of cancer was significantly higher in SSc patients, and especially in those who were male, than in the general population. Lung cancer was the most common cancer. Active surveillance for the detection of cancer should be performed in all SSc patients.

Entities:  

Mesh:

Year:  2009        PMID: 19308805     DOI: 10.1080/03009740802642062

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  23 in total

Review 1.  Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

2.  Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.

Authors:  Abdulla Watad; Dennis McGonagle; Nicola L Bragazzi; Shmuel Tiosano; Doron Comaneshter; Yehuda Shoenfeld; Arnon D Cohen; Howard Amital
Journal:  Oncoimmunology       Date:  2019-03-24       Impact factor: 8.110

Review 3.  Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature.

Authors:  David P Horowitz; Balazs Halmos; John Poneros; Joshua Sonett; Helen Remotti; Ryan J Burri
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 4.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

Review 5.  The relationships between cancer and autoimmune rheumatic diseases.

Authors:  Laura C Cappelli; Ami A Shah
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-02-03       Impact factor: 4.098

6.  Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.

Authors:  Takeru Igusa; Laura K Hummers; Kala Visvanathan; Carrie Richardson; Fredrick M Wigley; Livia Casciola-Rosen; Antony Rosen; Ami A Shah
Journal:  Ann Rheum Dis       Date:  2018-04-20       Impact factor: 19.103

7.  Mechanistic and clinical insights at the scleroderma-cancer interface.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  J Scleroderma Relat Disord       Date:  2017-10-05

Review 8.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

9.  Primary CNS lymphoma in scleroderma: a case series.

Authors:  Danielle M Robinett; Laura K Hummers; Meaghan Morris; Amy S Duffield; Ami A Shah
Journal:  J Scleroderma Relat Disord       Date:  2020-11-11

10.  Advances at the Interface of Cancer and Systemic Sclerosis.

Authors:  Christopher A Mecoli; Antony Rosen; Livia Casciola-Rosen; Ami A Shah
Journal:  J Scleroderma Relat Disord       Date:  2020-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.